Hyperprolactinaemia (raised prolactin, galactorrhoea)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Raised prolactin: confirm and look for the cause
Laboratory tests (repeat, at rest, if possible in another laboratory)
- Serum prolactin
- Serum β-hCG (premenopausal woman)if neededPregnancy is the first cause to rule out [1].
- TSH (if signs of hypothyroidism)if neededAt least in the presence of signs of hypothyroidism or pituitary hyperplasia on MRI; no demonstrated benefit of routine measurement [1].
- Serum creatinine with GFR (if renal impairment not known)if neededChronic renal failure raises prolactin; it is usually already known [1].
- Macroprolactin testing (state on the request)if neededNo gonadal impact, cycle disorders having another cause, normal or doubtful MRI, highly variable measurements [1].
- IGF-1 (macroadenoma on MRI)if neededFor a macroprolactinoma, look for co-secretion of growth hormone [1].
- LHif needednon-French guidelineAn American Family Physician review has them measured if hypogonadism is suspected [2]. The French consensus takes gonadal impact into account to point toward macroprolactinaemia, without specifying the tests [1]. See the page “Testosterone deficiency in men”.
- FSHif needednon-French guidelineAn American Family Physician review has them measured if hypogonadism is suspected [2]. The French consensus takes gonadal impact into account to point toward macroprolactinaemia, without specifying the tests [1]. See the page “Testosterone deficiency in men”.
- Total testosteroneif needednon-French guidelineAn American Family Physician review has them measured if hypogonadism is suspected [2]. The French consensus takes gonadal impact into account to point toward macroprolactinaemia, without specifying the tests [1]. See the page “Testosterone deficiency in men”.
- LHif needednon-French guidelineAn American Family Physician review has them measured if hypogonadism is suspected [2]. The French consensus takes gonadal impact into account to point toward macroprolactinaemia, without specifying the tests [1]. See the page “Secondary amenorrhoea”.
- FSHif needednon-French guidelineAn American Family Physician review has them measured if hypogonadism is suspected [2]. The French consensus takes gonadal impact into account to point toward macroprolactinaemia, without specifying the tests [1]. See the page “Secondary amenorrhoea”.
- oestradiolif needednon-French guidelineAn American Family Physician review has them measured if hypogonadism is suspected [2]. The French consensus takes gonadal impact into account to point toward macroprolactinaemia, without specifying the tests [1]. See the page “Secondary amenorrhoea”.
Do not order
- Dynamic tests (TRH, metoclopramide) first-line: unnecessary, and they must not guide the indication for MRI [1,3].
- Routine catheter placement and multiple samples: not justified, a single resting sample is enough [1].
- Routine discontinuation of the pill or of menopausal hormone therapy to measure prolactin: not justified in most cases [1].
- Prolactin measurement during pregnancy, including in a woman followed for microprolactinoma: not recommended [1].
On an antipsychotic or another drug raising prolactin
Laboratory tests
- Serum prolactin (repeat after stopping or changing the drug if possible)
- Serum β-hCG (premenopausal woman)if neededPregnancy remains the first cause to rule out [1].
Sources (9)
- Brue T, Delemer B, et le groupe de travail de la Société française d'endocrinologie. Diagnostic et prise en charge des hyperprolactinémies. Consensus d'experts de la SFE (congrès de Strasbourg, octobre 2005). Médecine Clinique Endocrinologie & Diabète, hors-série, septembre 2006. Version publiée : Brue T, Delemer B. Diagnosis and management of hyperprolactinemia: expert consensus - French Society of Endocrinology. Ann Endocrinol (Paris). 2007;68(1):58-64.
- Huang W, Molitch ME. Evaluation and management of galactorrhea. Am Fam Physician. 2012;85(11):1073-1080.
- Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722-40.
- Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab. 2002;87(2):581-8.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0343 (prolactine), 0884 (séparation chromatographique des formes moléculaires de la prolactine) et 7402 (hCG sanguine).
- National Institute for Health and Care Excellence (NICE, Royaume-Uni). Fertility problems: assessment and treatment. NICE guideline NG257, 31 mars 2026 (remplace CG156).
- Glezer A, Mendes Garmes H, Kasuki L, Martins M, et al. Diagnosis of hyperprolactinemia in women: a position statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Arch Endocrinol Metab. 2024;68:e230502.
- National Institute for Health and Care Excellence (NICE, Royaume-Uni). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178, 12 février 2014, dernière mise à jour le 4 septembre 2026.
- Kim HR, Kim SM, Kang WS, Jeon HJ, Jang SH, Jon DI, et al. Development of a guideline for antipsychotic-induced hyperprolactinemia in Korea using the ADAPTE process. Clin Psychopharmacol Neurosci. 2023;21(3):447-456.